PMEF
NVCR icon

Point72 Middle East FZE’s NovoCure NVCR Stock Holding History

Point72 Middle East FZE’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-47,682
Closed -$770K – 1763
2023
Q3 		$770K Buy
47,682
+43,702
+1,098% +$1.26M 0.03% 670
2023
Q2 		$165K Sell
3,980
-11,798
-75% -$733K ﹤0.01% 1108
2023
Q1 		$949K Buy
+15,778
New +$1.26M 0.03% 514

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Point72 Middle East FZE's NVCR Position: Q4 2023 in Review

Point72 Middle East FZE sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 47,682 shares — an estimated $770K sold.

Point72 Middle East FZE first reported a position in NVCR in Q1 2023 and held it in 3 quarters. The position peaked at $949K in Q1 2023. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Point72 Middle East FZE reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 47,682 NovoCure shares in Q4 2023, an estimated $770K.
  • Point72 Middle East FZE first reported a position in NovoCure in Q1 2023 and held it in 3 quarters.
  • Point72 Middle East FZE's NovoCure position peaked at $949K in Q1 2023.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.